HSI1 22,353.33 -488.29 223.62B
HSCEI1 7,536.31 -154.03 71.32B
Back    Zoom +    Zoom - Block Traded
Citi Raises HUTCHMED (00013.HK) TP to HKD45.3, Maintains Buy/High Risk Rating and Top Pick Status
2026-11-20 14:04:35
Citi published a research report stating that HUTCHMED (00013.HK) announced that sovleplenib has received approval from China's National Medical Products Administration (NMPA), ahead of the company's guidance for approval in 1H27. Sovleplenib is a highly selective oral Syk inhibitor and represents the company's first self-developed hematology product to enter commercialization, marking another successful expansion beyond its established oncology business.

The broker noted that the approval reduces strategic risks for HUTCHMED in immunology/hematology and enables the company to enter the autoimmune hematologic disease market, broadening its commercial portfolio beyond oncology. The asset has already achieved positive pivotal data in immune thrombocytopenia (ITP) and warm autoimmune hemolytic anemia (wAIHA), supporting further lifecycle expansion. Citi had previously assumed approval in 1H27, and the earlier-than-expected approval will help accelerate commercialization, with initial sales contribution potentially arriving earlier than previously forecast. The approval also eases investor concerns regarding CMC preparedness, while global regulatory and manufacturing risks have declined significantly.

Citi raised its revenue forecasts for HUTCHMED for each of 2026 to 2028 by 1%, while net profit forecasts were increased by 4%, 2% and 4%, respectively, as the broker now incorporates sovleplenib sales from 2026 and raises the probability of success (POS) to 100%. Citi lifted the TP from HKD43.2 to HKD45.3, maintained its Buy/High Risk rating, and retained the stock as its top pick. (da/j)~

AASTOCKS Financial News
Website: www.aastocks.com


This article was automatically translated by AI, the Chinese version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation.